{
    "nctId": "NCT01124695",
    "briefTitle": "Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer",
    "officialTitle": "A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 124,
    "primaryOutcomeMeasure": "Progression-free Survival by CYP2D6 Status in 2 Categories",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Stage III (locally advanced), metastatic, or recurrent disease\n  * Deemed not resectable\n* Estrogen-receptor and/or progesterone-receptor positive disease\n\n  * Receptor status is based on most recent results\n* Measurable or non-measurable disease\n* ECOG performance status 0-2\n* History of central nervous system (CNS) metastasis allowed provided it has been treated (surgery, radiotherapy, or radiosurgery) within the past 4 weeks and does not require medications to control symptoms\n* Total bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* Alanine transaminase (ALT) and aspartate transaminase (AST) \u2264 2.5 times ULN (\u2264 5 times ULN if liver metastases present)\n* Negative pregnancy test\n* Fertile patients must use effective nonhormonal contraception\n* Disease-free of prior invasive malignancies for \u2265 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\n* Prior chemotherapy, trastuzumab, or bevacizumab in the adjuvant setting allowed provided it has been completed \u2265 4 weeks before study therapy; other prior non-hormonal investigational agents in the adjuvant setting must have been completed at least 4 weeks prior to study registration and should be discussed with the study PI\n* Prior tamoxifen as adjuvant treatment is allowed as long as the patient did not have disease relapse or progression while on adjuvant tamoxifen or within 4 weeks of last dose\n* Treatment in the advanced setting must have been completed at least 2 weeks prior to study initiation\n* Prior aromatase inhibitors (e.g., anastrozole, letrozole, exemestane, aminoglutethamide) are allowed in the adjuvant or metastatic setting\n* At least 2 weeks since prior and no concurrent medications that are strong to moderate inhibitors of CYP2D6 and may alter tamoxifen citrate metabolism including, but not limited to, any of the following:\n\n  * Paroxetine (Paxil)\n  * Fluoxetine (Prozac)\n  * Bupropion (Wellbutrin)\n  * Quinidine (Cardioquin)\n* Concurrent radiotherapy to painful sites of bone disease or areas of impending fractures allowed provided the following criteria are met:\n\n  * Radiotherapy was initiated before study entry\n  * Sites of measurable or non-measurable disease are outside the radiotherapy port\n  * Recovered from prior radiotherapy\n\nExclusion Criteria:\n\n* Pregnant or nursing\n* Concurrent chemotherapy\n* Leptomeningeal disease\n* Non-protocol concurrent hormonal therapy\n* Medical or psychiatric conditions that would interfere with protocol compliance, the ability to provide informed consent, assessment of response, or anticipated toxicities\n* Prior tamoxifen for advanced disease\n* More than 2 lines of non-hormonal treatment in the locally advanced or metastatic setting, including trastuzumab (Herceptin), bevacizumab, or other biologics\n* Starting bisphosphonate therapy while receiving treatment on this study\n\n  * Patients who have begun receiving bisphosphonate therapy prior to registration may continue at the same intervals used prior to study registration",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}